PLX Share Price | Protalix Biotherapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Protalix Biotherapeutics, Inc.?

Market Cap: As of Jun 18, Protalix Biotherapeutics, Inc. has a market capitalization of 109.06 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Protalix Biotherapeutics, Inc. reported net sales of 59.76 million and a net profit of 3.91 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 43.21 million and total assets of 73.42 million.

Q: What does Protalix Biotherapeutics, Inc. do?

Overview: Protalix Biotherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.Financial Snapshot: Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market-cap: USD 109.06 Million (Micro Cap)Key Metrics: P/E: 32.00 Dividend Yield: 0.00% Debt Equity: -0.74 Return on Equity: 8.64% Price to Book: 2.41Contact Details: Address: 2 Snunit St., Science Park, POB 455, KARMIEL None: 2161401 Tel: 972 4 9028100 Fax: 972 4 9889489 Website: http://www.protalix.com

Q: Is Protalix Biotherapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Protalix Biotherapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by weekly MACD and KST indicators, which are both mildly bullish, along with a bullish signal from the Bollinger Bands. However, the daily moving averages remain mildly bearish, indicating some short-term weakness. The Dow Theory also confirms a mildly bullish outlook on both weekly and monthly time frames. In terms of performance, the stock has shown a strong 1-year return of 70.64%, significantly outperforming the S&P 500's 17.14% over the same period. However, over the 5-year and 10-year periods, the stock has underperformed relative to the S&P 500.

Q: Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. with a P/E of 4.74. Additionally, Protalix's EV to EBITDA ratio stands at 15.52, while its peers are demonstrating much lower ratios, suggesting a premium valuation relative to the industry.In comparison to its peers, Protalix Biotherapeutics shows a ROCE of 38.92% and a ROE of 8.64%, which are strong indicators of operational efficiency but do not justify its current valuation levels when compared to peers like Puma Biotechnology, which is classified as very attractive. The stock's recent performance against the S&P 500 is not available, but the current valuation metrics suggest that investors may want to exercise caution before investing at this price level.

Results Declared: Protalix Biotherapeutics, Inc. has declared results on 18 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

958.08 k

Shareholding (Dec 2025)

FII

3.04%

Held by 42 FIIs

DII

89.55%

Held by 9 DIIs

Promoter

0.00%

How big is Protalix Biotherapeutics, Inc.?

22-Jun-2025

As of Jun 18, Protalix Biotherapeutics, Inc. has a market capitalization of 109.06 million, with net sales of 59.76 million and a net profit of 3.91 million over the latest four quarters. The company reported shareholder's funds of 43.21 million and total assets of 73.42 million as of Dec 24.

View full answer

What does Protalix Biotherapeutics, Inc. do?

22-Jun-2025

Protalix Biotherapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins. As of March 2025, it reported net sales of $10 million and a net loss of $4 million, with a market cap of $109.06 million.

View full answer

Who are in the management team of Protalix Biotherapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Protalix Biotherapeutics, Inc. includes Chairman Zeev Bronfeld, CEO Dror Bashan, and Directors Pol Boudes, Gwen Melincoff, Amos Bar-Shalev, David Granot, and Aharon Schwartz. They oversee the company's strategic direction and operations.

View full answer

Is Protalix Biotherapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Protalix Biotherapeutics, Inc. has shifted to a mildly bullish trend, supported by positive weekly indicators and a strong 1-year return of 70.64%, despite underperforming the S&P 500 over the past 5 and 10 years.

View full answer

Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Protalix Biotherapeutics, Inc. is considered overvalued with a P/E ratio of 32 compared to its peer Puma Biotechnology's 4.74, despite strong operational efficiency metrics, indicating that investors should be cautious before investing.

View full answer

Compare Protalix Biotherapeutics, Inc. with Similar Stocks

Annexon, Inc.Calidi Biotherapeutics, Inc.Ocean Biomedical, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 231 Million (Micro Cap)

P/E

43.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.53

Return on Equity

10.20%

Price to Book

4.36

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Dec 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

21.71%

6 Months

8.67%

1 Year

-14.46%

2 Years

67.72%

3 Years

9.79%

4 Years

86.84%

5 Years

-58.56%

Protalix Biotherapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.22%

EBIT Growth (5y)

27.11%

EBIT to Interest (avg)

-0.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.74

Sales to Capital Employed (avg)

1.14

Tax Ratio

24.19%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.63%

ROCE (avg)

58.62%

ROE (avg)

6.33%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.36

EV to EBIT

31.86

EV to EBITDA

26.07

EV to Capital Employed

8.13

EV to Sales

3.28

PEG Ratio

0.28

Dividend Yield

ROCE (Latest)

25.53%

ROE (Latest)

10.20%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 20 Schemes (7.4%)

Foreign Institutions

Held by 42 Foreign Institutions (3.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -49.16% vs 14.01% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -329.17% vs 1,100.00% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.10",
          "val2": "17.90",
          "chgp": "-49.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "2.50",
          "chgp": "-272.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.20",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "2.40",
          "chgp": "-329.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-510.60%",
          "val2": "119.40%",
          "chgp": "-63.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.31% vs -18.47% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -327.59% vs -65.06% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.70",
          "val2": "53.40",
          "chgp": "-1.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "5.20",
          "chgp": "-176.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.10",
          "chgp": "9.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.60",
          "val2": "2.90",
          "chgp": "-327.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-104.30%",
          "val2": "73.40%",
          "chgp": "-17.77%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

9.10

17.90

-49.16%

Operating Profit (PBDIT) excl Other Income

-4.30

2.50

-272.00%

Interest

0.40

0.20

100.00%

Exceptional Items

0.00

Consolidate Net Profit

-5.50

2.40

-329.17%

Operating Profit Margin (Excl OI)

-510.60%

119.40%

-63.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -49.16% vs 14.01% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -329.17% vs 1,100.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

52.70

53.40

-1.31%

Operating Profit (PBDIT) excl Other Income

-4.00

5.20

-176.92%

Interest

1.20

1.10

9.09%

Exceptional Items

0.00

Consolidate Net Profit

-6.60

2.90

-327.59%

Operating Profit Margin (Excl OI)

-104.30%

73.40%

-17.77%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -1.31% vs -18.47% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -327.59% vs -65.06% in Dec 2024

All Annual Results

Company CV

About Protalix Biotherapeutics, Inc.

Protalix Biotherapeutics, Inc.

Pharmaceuticals & Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Company Coordinates

Company Details

2 Snunit St., Science Park, POB 455 , KARMIEL None : 2161401

Tel: 972 4 9028100

http://www.protalix.com

Registrar Details